These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 17507151)

  • 1. Obesity and prostate cancer: epidemiology and clinical implications.
    Buschemeyer WC; Freedland SJ
    Eur Urol; 2007 Aug; 52(2):331-43. PubMed ID: 17507151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity and prostate cancer: making sense out of apparently conflicting data.
    Freedland SJ; Platz EA
    Epidemiol Rev; 2007; 29():88-97. PubMed ID: 17478439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body mass index as a predictor of prostate cancer: development versus detection on biopsy.
    Freedland SJ; Terris MK; Platz EA; Presti JC
    Urology; 2005 Jul; 66(1):108-13. PubMed ID: 15992911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are findings from studies of obesity and prostate cancer really in conflict?
    Freedland SJ; Giovannucci E; Platz EA
    Cancer Causes Control; 2006 Feb; 17(1):5-9. PubMed ID: 16411047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthropometrics and prostate cancer risk.
    Littman AJ; White E; Kristal AR
    Am J Epidemiol; 2007 Jun; 165(11):1271-9. PubMed ID: 17395597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer.
    Skolarus TA; Wolin KY; Grubb RL
    Nat Clin Pract Urol; 2007 Nov; 4(11):605-14. PubMed ID: 17982437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity and prostate cancer.
    O'Malley RL; Taneja SS
    Can J Urol; 2006 Apr; 13 Suppl 2():11-7. PubMed ID: 16672123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review.
    Alcaraz A; Hammerer P; Tubaro A; Schröder FH; Castro R
    Eur Urol; 2009 Apr; 55(4):864-73. PubMed ID: 19027219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and the risk of prostate cancer (United States).
    Bradbury BD; Wilk JB; Kaye JA
    Cancer Causes Control; 2005 Aug; 16(6):637-41. PubMed ID: 16049801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The link between obesity and prostate cancer: the leptin pathway and therapeutic perspectives.
    Ribeiro R; Lopes C; Medeiros R
    Prostate Cancer Prostatic Dis; 2006; 9(1):19-24. PubMed ID: 16344847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and prostate cancer: a role for adipokines.
    Mistry T; Digby JE; Desai KM; Randeva HS
    Eur Urol; 2007 Jul; 52(1):46-53. PubMed ID: 17399889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.
    Briganti A; Karakiewicz PI; Chun FK; Suardi N; Gallina A; Abdollah F; Freschi M; Doglioni C; Rigatti P; Montorsi F
    Int J Urol; 2009 Aug; 16(8):676-81. PubMed ID: 19602006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.
    Paranhos M; Antunes A; Andrade E; Freire G; Srougi M
    BJU Int; 2009 Oct; 104(8):1130-3. PubMed ID: 19426190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
    Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
    Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
    Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database.
    Freedland SJ; Bañez LL; Sun LL; Fitzsimons NJ; Moul JW
    Prostate Cancer Prostatic Dis; 2009; 12(3):259-63. PubMed ID: 19581922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.
    Palma D; Pickles T; Tyldesley S;
    BJU Int; 2007 Aug; 100(2):315-9. PubMed ID: 17617138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.